Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M116Revenue $M7.0Net Margin (%)-541.0Z-Score2.5
Enterprise Value $M39.6EPS $-4.6Operating Margin %-548.0F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-541.0Higher ROA y-yY
Price/Book1.610-y EBITDA Growth Rate %0Quick Ratio19.6Cash flow > EarningsN
Price/Sales4.35-y EBITDA Growth Rate %0Current Ratio19.6Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-46.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)5ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M19.7ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ARGS

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

ARGS is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ARGS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Pharmstandard International S.10% Owner 2014-02-12Buy1,275,000$8-26.5 view
Underdown Brian J.Director, 10% Owner 2014-02-12Buy40,497$8-26.5 view
Cooperatieve AAC LS U.A.10% Owner 2014-02-12Buy36,416$8-26.5 view
Birner HubertDirector, 10% Owner 2014-02-12Buy39,873$8-26.5 view
van Deventer SanderDirector, 10% Owner 2014-02-12Buy36,416$8-26.5 view

Press Releases about ARGS :

    Quarterly/Annual Reports about ARGS:

      News about ARGS:

      Articles On GuruFocus.com
      Weekly 3-Year Low Highlights: VCRA, CLUB, ARGS, ONTX, BOTA Jun 08 2014 

      More From Other Websites
      Argos Therapeutics Presents Data Showing the Impact of HIV Antigen Sequence Divergence on Durable... Jul 21 2014
      Argos Therapeutics presents results from trial of AGS-004 Jul 21 2014
      Argos Therapeutics Presents Data Showing the Impact of HIV Antigen Sequence Divergence on Durable... Jul 21 2014
      Argos Therapeutics to Present at Two Upcoming Healthcare Conferences Jun 11 2014
      Weekly 3-Year Low Highlights: CLUB, ARGS, ONTX, BOTA Jun 08 2014
      Argos Therapeutics to Host Post-American Society of Clinical Oncology (ASCO) Conference Call and... Jun 05 2014
      Treatment With AGS-003 and Sunitinib Associated With Doubling of Expected Survival in Patients With... Jun 02 2014
      Argos Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference May 28 2014
      Argos Therapeutics Named as a Red Herring Top 100 North America Winner May 27 2014
      ARGOS THERAPEUTICS INC Financials May 23 2014
      Argos Therapeutics CSO Dr. Charles Nicolette to Join Panel Discussion on Challenges in Clinical... May 19 2014
      Argos Therapeutics COO Fred Miesowicz to Join Panel Discussion on Manufacturing Challenges in Cell... May 15 2014
      ARGOS THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 15 2014
      ARGOS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 13 2014
      Argos Therapeutics reports Q1 EPS ($1.05), may not compare to consensus (46c) May 13 2014
      Argos Therapeutics Reports First Quarter 2014 Financial Results May 13 2014
      Argos Therapeutics to Present Data Related to Clinical Development Program for AGS-003 During 2014... May 12 2014
      ARGOS THERAPEUTICS INC Files SEC form 10-K, Annual Report Mar 31 2014
      ARGOS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 27 2014
      Argos Therapeutics to Present at 21st Annual Future Leaders in the Biotech Industry Conference Mar 21 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide